论文部分内容阅读
目的:探讨赖诺普利对高血压患者血小板活化功能、血脂、胰岛素抵抗(IR)的干预作用。方法:对117例高血压患者用赖诺普利治疗4 周,治疗前后观察血中血小板颗粒膜蛋白(GMP-140)、空腹血糖(FBG)、空腹胰岛素(FINS)、胆固醇(CH)、高密度脂蛋白(HDL)、甘油三酯(TG),计算胰岛素敏感指数(ISI),并以32 例正常人对照。结果:赖诺普利有效降低高血压患者血压( P< 0.05)。并且显著降低FBG、FINS、TG、GMP-140,升高ISI(P<0.05)。CH、HDL无显著变化( P> 0.05)。结论:高血压病存在IR、血脂代谢异常,血小板粘附力增强。赖诺普利在有效降压同时,可以纠正基础代谢紊乱
Objective: To investigate the effects of lisinopril on platelet activation, blood lipid and insulin resistance (IR) in patients with essential hypertension. Methods: 117 patients with hypertension were treated with lisinopril for 4 weeks. The levels of GMP-140, fasting blood glucose (FBG), fasting insulin (FINS), cholesterol (CH) Density lipoprotein (HDL), triglyceride (TG), insulin sensitivity index (ISI) were calculated and 32 normal controls were used. Results: Lisinopril effectively reduced blood pressure in hypertensive patients (P <0.05). And significantly lower FBG, FINS, TG, GMP-140, increased ISI (P <0.05). CH, HDL no significant change (P> 0.05). Conclusion: Hypertension exists IR, dyslipidemia and platelet adhesion enhancement. Lisinopril in the effective antihypertensive at the same time, you can correct the basic metabolic disorders